Abstract
BackgroundBiomarkers of disease activity in IBD have variable performance when it comes to sensitivity and specificity. The clinical use of serum calprotectin remains unclear, but commercially available assays are now...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
